Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastric emptying study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Gastric emptying study. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-004811-21 Sponsor Protocol Number: s53584 Start Date*: 2011-11-07
    Sponsor Name:UZLeuven
    Full Title: The effect of Sildenafil citrate (Viagra ®) on stomach motility, gastric emptying and food intake in healthy volunteers
    Medical condition: study is conducted on healthy volunteers, no medical condition is investigated
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002889-32 Sponsor Protocol Number: CodeineII Start Date*: 2016-08-03
    Sponsor Name:KU Leuven
    Full Title: THE RELATIONSHIP BETWEEN GASTRIC MOTILITY AND EMPTYING AS MEASURED WITH AN INTRAGASTRIC BALLOON AND BREATH TESTING
    Medical condition: gastroparesis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007226-19 Sponsor Protocol Number: TZP-102-CL-G002 Start Date*: 2009-05-15
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic...
    Medical condition: The medical condition to be investigated is gastroparesis due to diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004946-41 Sponsor Protocol Number: s57223 Start Date*: 2014-11-19
    Sponsor Name:KULeuven
    Full Title: The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers
    Medical condition: healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023186-21 Sponsor Protocol Number: MOT114479 Start Date*: 2011-06-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist ...
    Medical condition: Diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002092-28 Sponsor Protocol Number: acotiamide1 Start Date*: 2017-04-19
    Sponsor Name:KULeuven - TARGID
    Full Title: The effect of acotiamide on gastric motility and satiation in healthy volunteers
    Medical condition: Funtional gastroenterological disorder: Functional Dyspepsia more specific the postprandial distress syndrome.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004180-13 Sponsor Protocol Number: OCARINA Start Date*: 2021-10-18
    Sponsor Name:KU Leuven
    Full Title: The effect of obeticholic acid on gut microbiota, gastric motility, accommodation, gastrointestinal peptide in healthy volunteers
    Medical condition: The study will focus on the underlying mechanisms of gastrointestinal motility and gut microbiota in healthy subjects.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10017782 Gastric emptying study PT
    20.1 100000004856 10061247 Intestinal functional disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002594-33 Sponsor Protocol Number: TZP-102-CL-G003 Start Date*: 2011-10-14
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated w...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002576-14 Sponsor Protocol Number: TZP-102-CL-G004 Start Date*: 2012-08-23
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associate...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004066-32 Sponsor Protocol Number: OB/ERYTH 2004-004066-32 Start Date*: 2006-02-01
    Sponsor Name:Silvia Delgado Aros
    Full Title: Reducción de la Ingesta Calórica en la Obesidad Mediante Modulación Farmacológica del Vaciamiento Gástrico Reduction of Caloric Intake in Obesity through Pharmacological Modulation of Gastric Empt...
    Medical condition: Obesidad/Sobrepeso Obesity/Overweight
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004438-32 Sponsor Protocol Number: MOT115816 Start Date*: 2012-04-25
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s...
    Medical condition: Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000594-81 Sponsor Protocol Number: S65020 Start Date*: 2021-05-07
    Sponsor Name:University Hospitals Leuven (UZ Leuven)
    Full Title: The effect of corticotropin release hormone on duodenal markers and gastric sensorimotor function in healthy volunteers
    Medical condition: To assess the effect of the CRH on duodenal mast cell count, eosinophil count, immune activation, mucosal permeability and gastric sensorimotor function and gastrointestinal symptoms.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008175-34 Sponsor Protocol Number: MOT111809 Start Date*: 2009-03-31
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor A...
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051153 Diabetic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003575-47 Sponsor Protocol Number: BP21572 Start Date*: Information not available in EudraCT
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multipl...
    Medical condition: Patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003250-13 Sponsor Protocol Number: 0099 Start Date*: 2015-05-06
    Sponsor Name:Theravance Biopharma R&D, Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic ...
    Medical condition: diabetic or idiopathic gastroparesis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    17.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003687-10 Sponsor Protocol Number: NALUGStrial Start Date*: 2022-01-26
    Sponsor Name:UZLeuven
    Full Title: Naloxegol for improving upper gastrointestinal symptoms and gastric emptying rate in patients with opioid induced constipation
    Medical condition: Opioid induced gastrointestinal dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10013225 Disorder gastrointestinal LLT
    20.1 100000004873 10079385 Opioid use disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003279-38 Sponsor Protocol Number: TZP-101-CL-G004 Start Date*: 2007-08-17
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G...
    Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001764-35 Sponsor Protocol Number: 120-0569-DZBL-2012 Start Date*: 2013-11-18
    Sponsor Name:Diabeteszentrum Bad Lauterberg
    Full Title: ANTIDIABETIC EFFECTS OF ADDING A DPP-4 INHIBITOR (SITAGLIPTIN) TO PRE-EXISTING TREATMENT WITH AN INCRETIN MIMETIC (LIRAGLUTIDE) IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMIN
    Medical condition: TYPE 2 DIABETES
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004997-23 Sponsor Protocol Number: M0003-C201 Start Date*: 2007-11-23
    Sponsor Name:Movetis NV
    Full Title: An exploratory, double-blind, randomized, stratified, placebo-controlled, repeated dose trial to investigate the efficacy of M0003 on symptoms suggestive for gastroparesis, to assess the pharmacody...
    Medical condition: Symptoms suggestive for gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001275-21 Sponsor Protocol Number: TAK-906-2002 Start Date*: 2019-06-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine ...
    Medical condition: Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    20.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 14:29:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA